Drug intelligence / Profile preview

Bamirastine

Development stage: Discontinued
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

Bamirastine (TAK-427) is a small molecule antiallergic agent developed by Takeda. It acts as a selective histamine H1 receptor antagonist, inhibiting ligand binding to the human H1 receptor and suppressing acute allergic reactions. Bamirastine demonstrated high selectivity for peripheral H1 receptors with minimal sedative side effects in preclinical studies. The drug was investigated for the treatment of allergic rhinitis and atopic dermatitis but development was discontinued after reaching phase II clinical trials.

Other names: bamirastinebamirastine hydrate

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Bamirastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bamirastine.

Explore the full profile